Affimed NV
Change company Symbol lookup
Select an option...
AFMD Affimed NV
ARVN Arvinas Inc
FOUR Shift4 Payments Inc
UK Ucommune International Ltd
CRDF Cardiff Oncology Inc
TRNR Interactive Strength Inc
OMGA Omega Therapeutics Inc
ACST Acasti Pharma Inc
PYPD PolyPid Ltd
ACRX AcelRx Pharmaceuticals Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Based in Germany

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Postmarket

Last Trade: Delayed
$0.4752

Change Since Close Change Since Close Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.: 0.0002 (0.04%)

Bid: --

Ask: --

B/A Size: --

Market Hours

Closing Price: $0.475

Day's Change: 0.0114 (2.46%)

Bid close: --

Ask close: --

B/A Size: --

Day's High: 0.4824

Day's Low: 0.4613

Volume (Average) Volume: 543,245 10-day average volume: 537,194: 543,245

Unable to locate that news article. Back to news results

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Postmarket

Change Since Close

Market Hours